Park Avenue Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Park Avenue Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,750	Closed	-$226K	–	1389
2024 Q2	$226K	Sell	2,750 -1,870	-40%	-$156K	﹤0.01%	1275
2024 Q1	$403K	Sell	4,620 -1,578	-25%	-$141K	0.01%	1056
2023 Q4	$598K	Buy	6,198 +1,117	+22%	+$98.8K	0.01%	842
2023 Q3	$450K	Buy	+5,081	New	+$452K	0.01%	885
2023 Q1	–	Sell	-2,560	Closed	-$265K	–	753
2022 Q4	$265K	Sell	2,560 -11	-0.4%	-$1.03K	﹤0.01%	1026
2022 Q3	$218K	Buy	+2,571	New	+$229K	﹤0.01%	1034
2020 Q3	–	Sell	-1,694	Closed	-$209K	–	742
2020 Q2	$209K	Buy	+1,694	New	+$168K	0.01%	629

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Park Avenue Securities's BMRN Position: Q3 2024 in Review

Park Avenue Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,750 shares — an estimated $226K sold.

Park Avenue Securities first reported a position in BMRN in Q2 2020 and held it in 7 quarters. The position peaked at $598K in Q4 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Park Avenue Securities reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Park Avenue Securities sold 2,750 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $226K.
Park Avenue Securities first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Park Avenue Securities's BioMarin Pharmaceuticals position peaked at $598K in Q4 2023.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Park Avenue Securities's 13F filing for Q3 2024, filed 3 Oct 2024.